Dose and duration of fenfluramine-phentermine therapy impacts the risk of significant valvular heart disease.
Lepor
N E
NE
Heart Center of Los Angeles, Los Angeles, California, USA.
Gross
S B
SB
Daley
W L
WL
Samuels
B A
BA
Rizzo
M J
MJ
Luko
S P
SP
Hickey
A
A
Buchbinder
N A
NA
Naqvi
T Z
TZ
D001022:Aortic Valve Insufficiency / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000503:physiopathology; D001067:Appetite Depressants / Q000008:administration & dosage / Q000009:adverse effects*; D001783:Blood Flow Velocity / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D018618:Echocardiography, Doppler, Color; D004562:Electrocardiography / Q000187:drug effects; D005260:Female; D005277:Fenfluramine / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D008944:Mitral Valve Insufficiency / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000503:physiopathology; D009200:Myocardial Contraction / Q000187:drug effects; D019370:Observation; D015588:Observer Variation; D010645:Phentermine / Q000008:administration & dosage / Q000009:adverse effects*; D012189:Retrospective Studies; D012307:Risk Factors; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D016278:Ventricular Function, Right / Q000187:drug effects
D001067:Appetite Depressants; D005277:Fenfluramine; D010645:Phentermine; D017367:Selective Serotonin Reuptake Inhibitors